Zymeworks Licenses ZW209 to Roche With $55 Million Upfront
Zymeworks will receive $55 million upfront and may earn milestone payments and royalties as Roche takes global development rights to ZW209.
Makkler Newsroom · Oct 23, 06:54 PM · 1 min read
Market closed· · USD · Data may be delayed
Avg. target $43.29 (+65.0%)
Prices may be delayed and are for informational purposes only - not investment advice.
Recent third-party headlines about this company, kept separate from Makkler's own editorial coverage and linking out to the publisher. Accuracy is the publisher's responsibility.